Navigation Links
Drugs to treat anemia in cancer patients linked to thromboembolism

NEW YORK Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. The findings will be published online on Nov. 10, 2009 in the Journal of the National Cancer Institute (ahead of the Dec. 2, 2009 print edition).

The anemia-reducing medications, known as erythropoiesis-stimulating agents (i.e., erythropoietin and darbopoietin) or ESAs, stimulate red blood cell production and are intended to reduce the number of blood transfusions required during chemotherapy. However, concerns about the risks of deep vein thrombosis or pulmonary embolism (manifestations of venous thromboembolism) and mortality exist.

"This research answers important questions about outcomes of ESAs when used in long-term clinical practice with oncology patients," said Dr. Hershman, the Florence Irving Assistant Professor of Medicine and Epidemiology at Columbia University Medical Center, whose research is dedicated to examining cancer survivorship. "While ESAs were given to reduce the need for blood transfusions, a substantial reduction in the use of blood transfusions was not observed. However, an increase risk of deep vein thrombosis or pulmonary embolism was confirmed."

"This analysis confirms the association between ESAs and venous thromboembolism, which was observed in previous meta-analysis," said Dr. Hershman. "This new finding is significant because where the meta-analysis looked at pooled data from randomized clinical trials, this data is from community practice real-life clinical settings where you can often see things that wouldn't necessarily show-up in a short-term, 12-week study. Additionally, this analysis included data from more than 50,000 patients including those with more advanced cancer or high-risk status, who therefore might not have been candidates for clinical trials."

Based on previous findings, in the spring of 2007, the FDA required a black-box warning on ESAs about the potential for venous thromboembolism, tumor promotion, and decreased survival in ESA users. The warning suggested limiting the use of ESAs to specific tumor types, durations, doses, and targeted hemoglobin levels. In addition, the Center for Medicare and Medicaid Services proposed eliminating or limiting coverage for ESAs as treatment for some cancers.

"But what is reassuring about our findings are that they don't show an increased risk of mortality when ESAs are given with chemotherapy," said Dr. Hershman.

Dr. Hershman and colleagues analyzed the association between use of ESAs and venous thromboembolism and overall survival in patients who were 65 years or older and diagnosed with colon, non-small cell lung, or breast cancer or diffuse large B-cell lymphoma, between 1991-2002. These cancers were chosen because they were thought to be common cancers for which ESAs were frequently used. Patients were identified in the Surveillance, Epidemiology, and End ResultsMedicare database, which at the time contained records of patients diagnosed with cancer in regions that represented approximately 14 percent of the U.S. population.

Results demonstrated that more patients who received an ESA developed deep vein thrombosis or pulmonary embolism, as compared to patients who did not. Overall survival was similar in both groups. The number of patients receiving ESAs increased approximately 10-fold from 1991 through 2002, with approximately 50 percent of patients with advanced cancer undergoing chemotherapy receiving ESAs by 2002. The rate of blood transfusion per year during the same time period, however, remained constant at 22 percent.

"Further efforts at monitoring use and long-term toxicity of expensive oncology drugs should be put in place to ensure that for any drug the benefits outweigh the risks in community practice," the authors write in the paper.

In the JNCI paper, the authors note that ESAs may be of particular interest from a public policy perspective because of the costs associated with their use. Total U.S. sales of ESAs were $10 billion in 2006, accounting for a greater Medicare Part B expenditure than any other drug.


Contact: Elizabeth Streich
Columbia University Medical Center

Related medicine news :

1. Breast Cancer Drugs May Fight Cervical Cancer, Too
2. Computerized support keeps prominence of name brand drugs at bay
3. Pay Less for Prescription Drugs
4. California American Water Celebrates No Drugs Down the Drain Week in Sacramento
5. How Safe Are Popular Reflux Drugs?
6. Cholesterol Drugs May Help Prevent Flu Deaths
7. Mark McGwires Message: Cheat, Do Drugs, Cover Up When Congress Investigates, Says Ex-White House Drug Spokesman Bob Weiner; World Series Should Test Both Teams During Games
8. Antipsychotic Drugs Spur Dramatic Weight Gain in Kids
9. Herbicides, Fibrate Drugs May Block Taste Receptors
10. Drugs for Inflammatory Bowel Might Increase Cancer Risk
11. Drugs for Irritable Bowel Might Increase Cancer Risk
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... private messaging application, announced today a significant contract that will provide its award-winning ... plans to build on the growing success of its Relay program, IBX Wire™, ...
(Date:10/13/2015)... ... 13, 2015 , ... e-con Systems Inc., a leading embedded design services company ... industry’s first RGB-IR pixel format camera with a USB 3.0 interface and e-CAM40_CUMI4682_MOD, ... of UVC USB 3.0 cameras, is based on the 1/3-inch OV4682 - a 4-megapixel ...
(Date:10/13/2015)... , ... October 13, 2015 , ... A child without ... why SmileCareClub , the leading remote invisible aligner system, has joined with ... otherwise go without it. For each aligner treatment plan purchased, SmileCareClub will donate one ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Protein is ... the body, including muscle, bone, and blood. But how much protein does the average ... than it might seem, according to the October 2015 issue of Harvard Men's ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... targets the unique health needs of new moms. Postnatal Omega-3, which has ... ), utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 oil. This breakthrough ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... LA JOLLA, Calif. , Oct. 13, 2015 /PRNewswire/ ... to revolutionize the practice of medicine, announced today the ... powered clinical research project that has the potential to ... San Diego, CA , at HLI,s ... open in 2016 in other US and International cities. ...
(Date:10/13/2015)... PARK, Calif. , Oct. 13, 2015 /PRNewswire/ ... of up to $100 million over five years ... Diseases (NIAID), part of the National Institutes of ... or treat acute or delayed effects of radiation ... , a division of SRI International will provide ...
(Date:10/13/2015)... MILFORD, Mass. , Oct. 13, 2015  SeraCare ... diagnostics manufacturers, announced today that the company,s precision medicine ... growing line of reference materials for next-generation sequencing (NGS)-based ... Mutation Mix-I (AF1-10) contains the same mixture of mutations ... the previously launched AF20 mix , but is ...
Breaking Medicine Technology: